期刊
MOLECULES
卷 26, 期 22, 页码 -出版社
MDPI
DOI: 10.3390/molecules26226907
关键词
GPR120; synthesis; type 2 diabetes; pharmacokinetic profiles
资金
- National Natural Science Foundation of China [81803360, 21675071]
- Major Project of Research and Development of Shandong Province [2019GSF108226]
- Shandong Provincial Administration of Traditional Chinese Medicine [2017-525]
- Doctoral Foundation of Liaocheng University [318051745]
Novel GPR120 agonists, including compound 11b, were designed and synthesized in this study, showing excellent blood glucose lowering effects in normal mice and diet-induced obese mice with no hypoglycemic side effects. Compound 11b demonstrated promising potential as a drug candidate for the treatment of T2DM.
GPR120 is a promising target for the treatment of type 2 diabetes (T2DM), which is activated by free fatty acids (FFAs) and stimulates the release of glucagon-like peptide-1(GLP-1). GLP-1, as an incretin, can enhance glucose-dependent secretion of insulin from pancreatic beta cells and reduce blood glucose. In this study, a series of novel GPR120 agonists were designed and synthesized to improve the stability and hydrophilicity of the phenylpropanoic acid GPR120 agonist TUG-891. Compound 11b showed excellent GPR120 agonistic activity and pharmacokinetic properties, and could reduce the blood glucose of normal mice in a dose-dependent manner. In addition, no hypoglycemic side effects were observed even at a dose of 100 mg/kg. Moreover, 11b showed good anti-hyperglycemic effects in diet-induced obese (DIO) mice. Molecular simulation illustrated that compound 11b could enter the active site of GPR120 and interact with ARG99. Taken together, the results indicate that compound 11b might be a promising drug candidate for the treatment of T2DM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据